| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 672-674 |
| Número de páginas | 3 |
| Publicación | Arteriosclerosis, Thrombosis, and Vascular Biology |
| Volumen | 45 |
| N.º | 5 |
| DOI | |
| Estado | Published - may 1 2025 |
Financiación
The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R35HL155649), a Merit award from the American Heart Association (23MERIT1036341), and an institutional support from the College of Medicine at the University of Kentucky to H.S. Lu. The content in this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
| Financiadores | Número del financiador |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | |
| Department of Pathology & Laboratory Medicine at the University of Kentucky College of Medicine | |
| National Institutes of Health (NIH) | R35HL155649 |
| American the American Heart Association | 23MERIT1036341 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Huella
Profundice en los temas de investigación de 'Is IDOL an Ideal Target for Treating Atherosclerosis?'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver